Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action

JAMA Neurology

Volumn 71, Issue 8, 2014, Pages 985-993

  Margolis, Jay M ^a   Chu, Bong L ^a   Wang, Zhixiao J ^b   Copher, Ronda ^b   Cavazos, Jose E ^c,d  

^a IBM WATSON HEALTH   (United States)

^b EISAI INC   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID DERIVATIVE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; DIAZEPAM; ETHOTOIN; ETIRACETAM; FELBAMATE; FOSPHENYTOIN SODIUM; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; SODIUM CHANNEL BLOCKING AGENT; SYNAPTIC VESICLE PROTEIN 2A BINDING AGENT; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN; ZONISAMIDE; 4 AMINOBUTYRIC ACID; CALCIUM CHANNEL BLOCKING AGENT; MEMBRANE PROTEIN; NERVE PROTEIN; PROTEIN BINDING; SV2A PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CONTROL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EMERGENCY HEALTH SERVICE; FEMALE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PARTIAL ONSET SEIZURE; PRIORITY JOURNAL; SEIZURE; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; ANALOGS AND DERIVATIVES; CLASSIFICATION; COHORT ANALYSIS; DRUG COMBINATION; EPILEPSIES, PARTIAL; HEALTH SERVICE; INSURANCE; MEDICATION COMPLIANCE; METABOLISM; MIDDLE AGED; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CALCIUM CHANNEL BLOCKERS; COHORT STUDIES; DRUG THERAPY, COMBINATION; EMERGENCY MEDICAL SERVICES; EPILEPSIES, PARTIAL; FEMALE; GAMMA-AMINOBUTYRIC ACID; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICATION ADHERENCE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PROTEIN BINDING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905970946     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.808     Document Type: Article

References (16)

1. Epilepsy Foundation. Epilepsy: just the facts. http://multivu.prnewswire. com/mnr/epilepsyfoundation/47010/docs/47010-EpilepsyFactsandFigures2010.pdf. Accessed May 29, 2014.
2. Brodie MJ, French JA. Management of epilepsy in adolescents and adults. Lancet. 2000;356 (9226):323-329. (Pubitemid 30459597)
3. Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc. 1996;71(6):576-586.
4. St Louis EK. Truly "rational" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects. Curr Neuropharmacol. 2009;7(2):96-105.
5. Knoester PD, Boendermaker AJ, Egberts ACG, et al. Cost-effectiveness of add-on lamotrigine therapy in clinical practice. Epilepsy Res. 2005;67(3):143-151. (Pubitemid 41676823)
6. Blais L, Sheehy O, St-Hilaire JM, Bernier G, Godfroid P, LeLorier JJ. Economic evaluation of levetiracetam as an add-on therapy in patients with refractory epilepsy [published correction appears in Pharmacoeconomics. 2005;23(9):944]. Pharmacoeconomics. 2005;23(5):493-503. (Pubitemid 40994137)
7. Brodie MJ, Sills GJ. Combining antiepileptic drugs: rational polytherapy? Seizure. 2011;20(5):369-375.
8. Lee JW. Dworetzky B. Rational polytherapy with antiepileptic drugs. Pharm. 2010;3(8):2362-2379. doi:10.3390/ph3082362.
9. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
10. Farley JF, Harley CR, Devine JW. A comparison of comorbidity measurements to predict healthcare expenditures. Am J Manag Care. 2006;12(2):110-119.
11. Malerba A, Ciampa C, De Fazio S, et al. Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy. Epilepsy Res. 2010;91(2-3):273-282.
12. Nicholas JM, Ridsdale L, Richardson MP, Ashworth M, Gulliford MC. Trends in antiepileptic drug utilisation in UK primary care 1993-2008: cohort study using the General Practice Research Database. Seizure. 2012;21(6):466-470.
13. Cramer JA, Mintzer S, Wheless J, Mattson RH. Adverse effects of antiepileptic drugs: a brief overview of important issues. Expert Rev Neurother. 2010;10(6):885-891.
14. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults: the Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med. 1992;327(11):765-771.
15. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985;313(3):145-151. (Pubitemid 15047456)
16. Buck D, Jacoby A, Baker GA, Chadwick DW. Factors influencing compliance with antiepileptic drug regimes. Seizure. 1997;6(2):87-93. (Pubitemid 27220013)